Related Experiment Videos
Hemoglobin solutions in experimental cardioplegia
T I Pristoupil1, M Vrána, J Havlícková
1Institute of Hematology and Blood Transfusion, Prague, Czechoslovakia.
The International Journal of Artificial Organs
|October 1, 1989
Summary
Adding hemoglobin to cardioplegic solution significantly protects the heart from ischemic damage. This protective effect is primarily due to hemoglobin's buffering capacity, not oxygen transport.
Area of Science:
- Cardiovascular Surgery
- Biochemistry
- Organ Preservation
Background:
- Ischemic heart damage is a major concern during cardioplegia.
- Standard cardioplegic solutions aim to minimize myocardial injury.
- Novel additives are explored to enhance cardiac protection.
Purpose of the Study:
- To evaluate the efficacy of stroma-free hemoglobin solution in protecting the heart from ischemic damage.
- To compare the protective effects of hemoglobin-containing cardioplegia with standard solutions.
- To elucidate the mechanism behind hemoglobin's cardioprotective properties.
Main Methods:
- An experimental rat heart model was used for cardioplegia and transplantation.
- Hearts underwent three hours of cardiac arrest at 20°C.
- Biochemical in vitro experiments were conducted to assess oxyhemoglobin's effects.
Main Results:
- Hemoglobin addition significantly protected the heart against ischemic damage.
- Hearts treated with oxyhemoglobin showed strong contractions post-cardioplegia, comparable to histidine-buffered solutions.
- In vitro studies indicated buffering capacity as the primary mechanism of protection.
Conclusions:
- Stroma-free hemoglobin solution offers significant cardioprotection during cardioplegia.
- The primary benefit of hemoglobin in this context is its buffering capacity.
- Oxygen transport by hemoglobin plays a minimal role in prolonged cardioplegia without reoxygenation.